preclinical drug development

RetiNova Therapeutics is developing a new class of regenerative therapies designed to reverse vision loss associated with retinal ischemia. Its Noregen™ (CTR-107) program, a synthetic protein modeled after norrin, is in late preclinical development for diabetic macular edema (DME) and retinal vein occlusion (RVO), aiming for disease modification and regeneration of functional retinal tissue.

regenerative therapy research

Endobios Biotech is an EU-based startup advancing a potential first-in-class small molecule anticonvulsant, currently in the early preclinical stages of drug development. Its lead candidate ENB-002 is a new chemical scaffold (molecular weight <300 g/mol) based on unpublished fungal-derived compounds, with in vivo anticonvulsant activity in a mouse model, preliminary blood-brain barrier permeability data, and secondary capacity against neuropathic pain.

drug discoverysmall molecule development

FibroNox has pioneered the development of patented first-in-class treatments to mitigate life-threatening fibrotic diseases, including selective Nox4 inhibitors and Nrf2 activators. Its small-molecules have demonstrated efficacy in preclinical studies for halting and reducing established fibrosis. The company focuses on idiopathic pulmonary fibrosis (IPF) as its primary indication, with preclinical data supporting other fibrotic indications, and is developing inhaled therapeutic delivery for pulmonary fibrosis.

inhaled drug deliverysmall-molecule therapeutics

GenrAb is harnessing the power of human immunity to develop therapies that can protect and treat patients with neurological diseases. Its proprietary Antibody Gene Signature (AGS) technology has identified over 400 potentially therapeutic fully-human monoclonal antibodies (mAbs) to treat neurological disorders. Its lead mAb, TGM-010, targets a conserved neurodegenerative pathway and has demonstrated reduced disability in preclinical models.

antibody discoverymonoclonal antibody cloning

Jaya Biosciences is a privately held preclinical-stage life sciences company developing CNS-directed gene therapies for genetically defined neurodegenerative diseases, including Alzheimer's, Parkinson's, and frontotemporal dementia. Its lead therapy JB111 is an experimental CNS-directed AAV9-mediated PPT1 gene therapy being developed for Alzheimer's disease associated with PPT1 haploinsufficiency.

CNS-directed AAV9-mediated gene therapygene therapy development